line decor
  HOME  ::  
line decor
Cartilage Oligomeric Matrix Protein (COMP) ELISA Kit
  • COMP
  • Thrombospondin-5
  • TSP-5
CONCLUSIONS: These results indicate sCOMP is elevated in patients with knee OA
and is sensitive to OA disease progression. Future research studies with a higher
level of evidence should be conducted to investigate the use of this biomarker as
an indicator for OA development and progression.
Hoch JM et al. Osteoarthritis Cartilage. 2011 Dec;19(12):1396-404

Deficiency of cartilage oligomeric matrix protein causes dilated cardiomyopathy

Alterations in cardiac extracellular matrix are involved in dilated cardiomyopathy (DCM) and its progression to heart failure. The matricellular protein cartilage oligomeric matrix protein (COMP) has been indicated localized in the heart. However, the role of COMP in cardiac homeostasis and disease remains elusive. COMP (-/-) mice, both male and female, developed DCM spontaneously at young age (3-5 months), with impaired cardiac function. Assessment of postnatal COMP (-/-) heart at 1 month, although functionally normal, revealed severe cardiac ultrastructure defect, in parallel with cardiomyocyte apoptosis, myofilament loss, connexin-43 deficiency and matrix metalloproteinase activation. Decreased COMP expression was observed in the heart sample of DCM patients compared with donor heart. Mechanistically, COMP (-/-) heart exhibited reduced integrin β1 expression and signaling. Ectopic expression of COMP or integrin β1 rescued COMP-deficiency-induced cardiomyocyte apoptosis, myofilament dissolution, and connexin-43 aberrance. Additionally, COMP directly bonded to the extracellular β-tail domain of integrin β1, prevented integrin β1 ubiquitination/degradation, and maintained the cardiac homeostasis. COMP-integrin β1 axis is a potential target of DCM.
Huang Y et al. Basic Res Cardiol. 2013 Sep;108(5):374. 

Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive and life threatening disease with median survival of 2.5-3 years. The IPF lung is characterized by abnormal lung remodeling, epithelial cell hyperplasia, myofibroblast foci formation, and extracellular matrix deposition. Analysis of gene expression microarray data revealed that cartilage oligomeric matrix protein (COMP), a non-collagenous extracellular matrix protein is among the most significantly up-regulated genes (Fold change 13, p-value <0.05) in IPF lungs. This finding was confirmed at the mRNA level by nCounter® expression analysis in additional 115 IPF lungs and 154 control lungs as well as at the protein level by western blot analysis. Immunohistochemical analysis revealed that COMP was expressed in dense fibrotic regions of IPF lungs and co-localized with vimentin and around pSMAD3 expressing cells. Stimulation of normal human lung fibroblasts with TGF-β1 induced an increase in COMP mRNA and protein expression. Silencing COMP in normal human lung fibroblasts significantly inhibited cell proliferation and negatively impacted the effects of TGF-β1 on COL1A1 and PAI1. COMP proteinconcentration measured by ELISA assay was significantly increased in serum of IPF patients compared to controls. Analysis of serum COMP concentrations in 23 patients who had prospective blood draws revealed that COMP levels increased in a time dependent fashion and correlated with declines in force vital capacity (FVC). Taken together, our results should encourage more research into the potential use of COMP as a biomarker for disease activity and TGF-β1 activity in patients with IPF. Hence, studies that explore modalities that affect COMP expression, alleviate extracellularmatrix rigidity and lung restriction in IPF and interfere with the amplification of TGF-β1 signaling should be persuaded.
Vuga LJ et al. PLoS One. 2013 Dec 20;8(12):e83120

Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articularcartilage damage and/or the therapeutic efficacy of treatments

Cartilage oligomeric matrix protein (COMP) is a tissue-specific noncollagenous protein that was first detected in the serum and the synovial fluid of patients suffering from rheumatic disorders, such as rheumatoid arthritis, reactive arthritis, juvenile chronic arthritis, and osteoarthritis. In this review, the authors consider serum COMP levels in different diseases and discuss their study of patients with rheumatoid arthritis treated with anti-TNF-alpha, to evaluate whether COMP is able to predict a rapid and sustained clinical response to these drugs. They observe that patients with high COMP levels have a lower ACR 70 response independently of the state of systemic inflammation, and conclude that COMP seems to have a pathogenetic role that is independent of the mechanisms regulating inflammatory processes.
Morozzi G ET AL. Ann N Y Acad Sci. 2007 Jun;1108:398-407.

human comp elisa kit from aviscera bioscience

Code No.: SK00486-01
Size: 96 T
Price: $360.00 USD
Standard range:39-2500 pg/ml
Sensitivity: 10 pg/ml
Sample type: plasma, serum
Dilution factor: 200
Inter-CV: 8-10%
Data Sheet: PDF

recombinant recombinant recombinant recombinant
Code No.
Price ($)
Cartilage Oligomeric Matrix Protein (COMP) (Human) ELISA Kit
96 T
Cartilage Oligomeric Matrix Protein (COMP) (Human) standard
Cartilage Oligomeric Matrix Protein (COMP) (Human) Control
Anti Cartilage Oligomeric Matrix Protein (COMP) (Human) IgG Biotinylated
Anti Cartilage Oligomeric Matrix Protein (COMP) (Human) MAB plate